Summary: KQED speaks with MAPS Founder Rick Doblin, Ph.D., and Army SGT (R) Jon Lubecky about the Food and Drug Administration’s recent decision to grant Expanded Access to MDMA-assisted psychotherapy for PTSD. “The FDA is recognizing that there’s a humanitarian crisis with many, many millions of people that have treatment-resistant PTSD,” explains Doblin.
Originally appearing here.
